Method of treating metastatic cancer in a subject with a protein inhibitor

Patent metadata

Field	Value
Publication number	US-11484536-B2
Application number	US-202016937995-A
Country	US
Kind code	B2
Filing date	Jul 24, 2020
Priority date	Jul 24, 2020
Publication date	Nov 1, 2022
Grant date	Nov 1, 2022

Abstract

A method of treating metastatic cancer in a subject in need thereof including administering an effective amount of a capping protein Z inhibitor to the subject. A method of inhibiting metastasis of cancer cells including administering an effective amount of a capping protein Z inhibitor.

First claim

The invention claimed is:

1. A method of treating metastatic cancer in a subject, wherein the metastatic cancer is selected from the group consisting of breast cancer, lung cancer, and a combination thereof, comprising administering an effective amount of a capping protein Z stabilizer to the subject, wherein the capping protein Z stabilizer inhibits endosomal trafficking and comprises the following structure:

wherein:
R 1 is a hydrogen atom, a methyl group, a cyano group, an ethynyl group, an ethoxycarbonyl group, or a phenyl group;
R 4 is a hydrogen atom, a chloro or a fluoro group; and
L is a linker group of —(CH 2 ) m — or —(CH 2 CH 2 O) m — with m being 3, 4 or 5, and m′ being 2.

2. A method of treating metastatic cancer in a subject comprising administering an effective amount of a capping protein Z stabilizer to the subject, wherein the metastatic cancer is selected from the group consisting of breast cancer, lung cancer, and a combination thereof, wherein the capping protein Z stabilizer inhibits endosomal trafficking and comprises a structure of Formula (II):

3. The method of claim 1 , wherein the capping protein Z stabilizer is administered to the subject by a route selected from the group consisting of oral delivery, intravenous delivery, intradermal delivery, intraperitoneal delivery and intramuscular delivery.

4. The method of claim 1 , wherein the capping protein Z stabilizer is administered in combination with one or more chemotherapy drug to the subject.

5. The method of claim 4 , wherein the chemotherapy drug is selected from doxorubicin, taxol, 5-Fu, or temirolimus.

6. A method of inhibiting metastasis of cancer cells, wherein the cancer cells are selected from the group consisting of breast cancer, lung cancer, and a combination thereof, comprising administering to the cancer cells an effective amount of a capping protein Z stabilizer, wherein the capping protein Z stabilizer inhibits endosomal trafficking and comprises the following structure:

wherein:
R 1 is a hydrogen atom, a methyl group, a cyano group, an ethynyl group, an ethoxycarbonyl group, or a phenyl group;
R 4 is hydrogen atom, a chloro or a fluoro group; and
L is a linker group of —(CH 2 ) m — or —(CH 2 CH 2 O) m — with m being 3, 4 or 5, and m′ being 2.

7. A method of inhibiting metastasis of cancer cells, wherein the cancer cells are selected from the group consisting of breast cancer, lung cancer, and a combination thereof, comprising administering to the cancer cells an effective amount of a capping protein Z stabilizer, wherein the capping protein Z stabilizer inhibits endosomal trafficking and comprises, a structure of Formula (II):

8. The method of claim 6 , wherein the capping protein Z stabilizer is administered to the cancer cells in combination with one or more chemotherapy drug.

9. The method of claim 8 , wherein the chemotherapy drug is selected from doxorubicin, taxol, 5-Fu, or temirolimus.

10. The method of claim 7 , wherein the capping protein Z stabilizer is administered to the cancer cells in combination with one or more chemotherapy drugs.

11. The method of claim 10 , wherein the chemotherapy drug is selected from doxorubicin, taxol, 5-Fu, or temirolimus.

Assignees

• Univ City Hong Kong
• 6J Biotechnology Hong Kong Ltd
• 6J Biotechnology Ltd

Inventors

• Yue Jianbo
• Zhang Qingru
• Ye Zuodong
• Wang Dawei
• Zhu Kaiyuan

Classifications

• A61K31/436

  the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin · CPC title

• A61K31/704

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61K31/337 Primary

  having four-membered rings, e.g. taxol · CPC title

• A61K31/5377 Primary

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title